Premium
Serum Neopterin Monitoring and Vitamin E‐Modified, Regenerated Hemodialyzer Membrane Influence on Biocompatibility
Author(s) -
Yoshida Katsunori,
Kitauchi Takanori,
Kimura Shouki,
Yoneda Tatsuo,
Uemura Hirotsugu,
Ozono Seiichirou,
Hirao Yoshihiko
Publication year - 2002
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2002.6729_2.x
Subject(s) - neopterin , biocompatibility , cellulose triacetate , membrane , hemodialysis , medicine , chemistry , immunology , biochemistry , organic chemistry
The exposure of blood to hemodialysis membranes results in numerous phenomena and/or complications in hemodialyzed patients, which have an influence on the quality of life (QOL) of those patients. A vitamin E‐modified regenerated cellulose membrane (E‐membrane) was developed to act as a scavenger for reactive oxygen species causing complications in hemodialysis patients. Neopterin (NEOP) is a metabolite derived from guanosine triphosphate with the production and release of NEOP being induced in monocytes and macrophages by cytokines such as interferon‐γ (IFN‐γ). Serum neopterin levels are shown to be a reactive marker of bioincompatibility of dialysis membranes in hemodialysis patients. The following report evaluates the usefulness of serum NEOP as a marker for the biocompatibility of the E‐membrane hemodialyzer in a clinical study. In the clinical study, where extracorporeal ultrafiltration strategies with E‐membranes were employed, the serum levels of NEOP were lower than those in patients using cellulose triacetate membranes (C‐membranes). In the long‐term evaluation of the biocompatibility of E‐ and C‐membranes, the increase of serum neopterin levels in the C‐membrane was higher than those in the E‐membrane. In conclusion, the evaluation of serum neopterin levels during hemodialysis shows that the E‐membrane has a good biocompatibility in hemodialyzed patients.